Early use of naloxone in shock - A clinical trial

Chaim Putterman, Pinchas Halpern, Yigal Leykin, Patrick Sorkine, Eran Geller, Simon Bursztein

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Naloxone hydrochloride (N) 0.4-1.2 mg i.v. was administered during 10 episodes of shock (8 septic and 2 cardiogenic) in 9 adult patients. Shock was defined as systolic blood pressure (SBP) ≤90 mmHg and urine output <0.5 ml/h and signs and symptoms of hypoperfusion lasting for >-30 min, despite fluid loading to a CVP 5 cmH2O above baseline. N was given as early as 30 min after onset of shock and resulted in an increase of SBP from a mean of 75 ± 10 to a mean of 130 ± 25 mmHg maximum (P < 0.01). Within 10-60 min urine output increased from 16 ± 12 to 122 ± 56 ml/h, heart rate, CVP and arterial blood gas tensions remained unchanged. No side effects were observed. Naloxone, even in small doses, may improve hemodynamic parameters in human shock, provided it is administered very early.

Original languageEnglish (US)
Pages (from-to)185-190
Number of pages6
Issue number3
StatePublished - Apr 1986
Externally publishedYes


  • Naloxone
  • Shock

ASJC Scopus subject areas

  • Emergency Medicine
  • Emergency
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Early use of naloxone in shock - A clinical trial'. Together they form a unique fingerprint.

Cite this